Vertex, CRISPR Gain ‘Historic’ Nod in UK for Exa-Cel. But Will Cost Watchdogs Embrace the Gene Editing Therapy?

Vertex and CRISPR Therapeutics have scored authorization in the UK for their exa-cel gene therapy to treat patients with severe forms of sickle cell and transfusion-dependent beta thalassemia, two genetic disorders of the blood.